What Happened
- The patent on semaglutide — the active ingredient in blockbuster obesity and diabetes drugs Ozempic and Wegovy — expired in India on March 20, 2026, triggering an immediate generic drug launch.
- Over 50 branded generic versions are expected to enter the Indian market, with major pharmaceutical companies including Mankind Pharma, Sun Pharmaceutical, Dr. Reddy's Laboratories, Ajanta Pharma, and Lupin gearing up for launch.
- Generic semaglutide prices are projected to fall 30–75% below the innovator drug price, potentially reaching a 90% reduction at peak competition — from thousands of rupees per dose to a few hundred.
- The Indian market for GLP-1 receptor agonists (the drug class semaglutide belongs to) is projected to grow nearly five-fold from ₹10 billion in 2025 to ₹50 billion by 2030, per analyst estimates.
- A Delhi High Court ruling allowing Dr. Reddy's Laboratories to continue manufacturing semaglutide cleared the legal path for generics, rejecting Novo Nordisk's attempt to extend patent protection.
Static Topic Bridges
Indian Patents Act 1970: Section 3(d) and Evergreening Prevention
Section 3(d) of the Patents Act 1970 is India's most globally noted pharmaceutical patent provision. It bars the grant of patents for new forms of known substances — such as new salts, esters, polymorphs, or isomers — unless the applicant demonstrates a significant enhancement of known efficacy. This was specifically designed to prevent "evergreening," the practice by which pharmaceutical companies seek fresh patents on trivial modifications to extend monopoly protection beyond the original patent term. The Supreme Court upheld this provision in the landmark Novartis AG v. Union of India case (2013), rejecting Novartis's patent on imatinib mesylate (Gleevec).
- Section 3(d) was added to the Patents Act during the 2005 amendment that brought India into TRIPS compliance after the WTO TRIPS Agreement obligations kicked in.
- "Efficacy" under Section 3(d) means therapeutic efficacy — not merely bioavailability or physical properties — as confirmed by the Supreme Court in Novartis (2013).
- India does not grant product patents on pharmaceutical molecules known before 1995 (TRIPS transition period) — this is the reason original semaglutide never had a product patent in India.
- The Novo Nordisk case in Delhi High Court involved secondary patents (formulation, delivery device) — not the core molecule patent — which courts have been scrutinising more carefully.
- Section 3(d) is considered one of the most progressive pharmaceutical patent provisions globally, often cited as a model by developing countries.
Connection to this news: The expiry of semaglutide's core patent and the rejection of Novo Nordisk's secondary patent attempt are direct applications of India's anti-evergreening framework — precisely the system Section 3(d) was built to create.
Compulsory Licensing Under Section 84 of the Patents Act
Section 84 of the Patents Act 1970 allows any person to apply for a compulsory licence (CL) to manufacture a patented drug after three years from the grant of the patent, if: (a) the reasonable requirements of the public have not been satisfied, (b) the drug is not available at a reasonably affordable price, or (c) the patent is not worked in India. India's first — and so far only — compulsory licence was granted in 2012 by the Patent Controller for sorafenib tosylate (Nexavar), a cancer drug, to Natco Pharma against Bayer AG.
- Section 84 CL allows domestic manufacture and sale but not export (unless under Section 92A for least-developed countries).
- Section 92: Government can issue compulsory licences for government use or national emergency without the three-year waiting period.
- The 2012 Natco-Bayer CL required Natco to pay a 6% royalty to Bayer and supply the drug at ₹8,880/month vs. Bayer's ₹2.8 lakh/month — a 97% price reduction.
- In the case of semaglutide, CL is not required because the core patent has naturally expired — the generic market operates without a licence.
- TRIPS Agreement (Article 31) permits CL under national emergency, non-commercial government use, and anti-competitive practices.
Connection to this news: With semaglutide's patent expiring naturally, CL is not needed — but understanding when and why CL was designed is essential context for evaluating India's pharmaceutical policy architecture, especially as new GLP-1 follow-on drugs may seek long patent lives.
India as "Pharmacy of the World" and Generic Drug Industry
India is the world's largest supplier of generic medicines by volume, supplying approximately 20% of global generics output and 60% of global vaccine supply. The generic pharmaceutical sector employs over 3.5 million people and exports to over 200 countries. India's comparatively low cost of manufacturing (estimated 30–35% lower than US), strong chemistry expertise, and the legal framework around Section 3(d) and compulsory licensing have combined to make India the default source of affordable medicines for low- and middle-income countries. The HIV/AIDS treatment revolution of the 2000s — where Indian generics slashed antiretroviral drug prices from $10,000/year to under $150/year — is the most cited precedent for the potential impact of semaglutide generics.
- India's pharmaceutical exports were approximately $27.9 billion in FY24 — the largest category of manufactured exports.
- The top export destinations are the US (30%), UK, South Africa, and other developing nations.
- Drug Price Control Order (DPCO) 2013 — under the Essential Commodities Act — allows the National Pharmaceutical Pricing Authority (NPPA) to cap prices of essential medicines listed in the National List of Essential Medicines (NLEM).
- Semaglutide is not currently in the NLEM, meaning generic manufacturers can price freely within market competition — though NPPA can intervene if prices are deemed unreasonable.
- Jefferies Investment Bank projects the Indian semaglutide market alone could reach $1 billion in the medium term.
Connection to this news: The semaglutide patent expiry is the latest instance of India's generic pharmaceutical model potentially reshaping global access to a blockbuster drug — the same pattern observed with HIV antiretrovirals, making it a high-relevance precedent for UPSC Mains.
Obesity as a Public Health and Economic Policy Challenge
Globally, over 1 billion people are estimated to be obese, with obesity-related conditions (type 2 diabetes, cardiovascular disease, certain cancers) accounting for massive public health costs. India faces a dual burden of malnutrition and a rapidly growing incidence of obesity and metabolic syndrome, concentrated in urban areas. The availability of affordable GLP-1 drugs could shift the cost-benefit calculus of treating obesity from lifestyle interventions (which require sustained behaviour change) to pharmacological management (a single weekly injection).
- India has approximately 135 million people with diabetes (largest diabetic population globally) — a significant overlap with the semaglutide target population.
- Urban obesity prevalence in India: approximately 22–25% of adults (NFHS-5 data); rising rapidly.
- Novo Nordisk's Ozempic (type 2 diabetes) and Wegovy (obesity) were priced at approximately $900–$1,000/month in the US.
- Generic semaglutide in India is expected to be priced at ₹2,000–5,000/month initially, falling further with competition — vs. Novo Nordisk's branded price of ~₹15,000–20,000/month.
- WHO included semaglutide on its list of essential medicines for obesity in 2023, signalling global recognition of its therapeutic importance.
Connection to this news: Affordable generic semaglutide directly addresses India's diabetes and obesity burden — but the distributional access question (whether poorer populations will benefit or generics will remain urban middle-class products) is the key policy challenge going forward.
Key Facts & Data
- Semaglutide core patent expired in India: March 20, 2026
- 50+ branded generics expected; key companies: Mankind Pharma, Sun Pharma, Dr. Reddy's, Ajanta, Lupin
- Price reduction projected: 30–75% initially; up to 90% at peak competition
- Indian GLP-1 market projection: ₹10 billion (2025) → ₹50 billion (2030) — 5x growth
- Section 3(d), Patents Act 1970: bars trivial patent modifications unless therapeutic efficacy enhancement proven
- India's landmark compulsory licence: Natco-Bayer (2012) for sorafenib, Section 84
- India supplies ~20% of global generic medicines by volume; $27.9 billion pharmaceutical exports FY24
- 135 million diabetics in India — largest diabetic population globally (primary target for semaglutide)
- WHO added semaglutide to the essential medicines list for obesity (2023)